The term "biomarker" is used from 1980. Nowadays, diagnosis/prognosis and research in medical science are more concerned with the discovery and utilization of a number of biomarkers. The information in the library of biomarkers is rising day by day as their major concerns relate diseases, pathogenicity or pharmacology in a variety of hosts. Taking into account, we summarize a number of biomarkers in a number of diseases in human. It includes the name and their up-and/or down expressions in those situations. However, no description was plugged with the individual fact.
Introduction
Biological markers are known as "biomarkers", generally refers to a measurable indicator of some biological states or conditions. Biomarkers can be of any kind, including omics data, like DNA/RNA sequences, proteins, mutations and other attributes of an organism (Dix et al., 2016 ).
An ideal biomarker should be like: -a finger-print, having analytical validity and the estimated parameter must accurately and clearly discern between altered/normal status and treatment response/nonresponse of a patient. Specific tests used to identify the biomarkers should be accurate, reliable and reproducible; -a mirror, reflecting the disease or treatment in question, thereby providing clinical validity. In other words, the ideal biomarker should document the activity or progression of the disease and assess any effect of the treatment administered. However, it should not be influenced by some other factors such as age, sex, stress, diet, exercise or genetic determinants. Otherwise, it must have feasibility and being practical to identify and measure rather than variability according to the type of sample collection, processing procedures or methods used for its identification; -non-invasiveness in samples, techniques, and pathophysiological states as well as time and cost effectiveness in treatment courses (Scotton et al., 2014) .
Most often biomarkers are used as diagnostic tools, or for anticipating the severity of the disease course (diagnostic/prognostic biomarker). Diagnostic biomarkers are used to separate the healthy population from the affected, or to distinguish between different patient groups based on phenotype severity; -for defining the pharmacokinetic and pharmacodynamic action of drugs and drug response mechanisms (predictive/therapeutic biomarkers). A predictive biomarker highlights the different outcomes of a particular treatment, discriminating between patient categories based on the irresponse to it (Scotton et al., 2014) .
It is noteworthy that, biomarkers are often measured and evaluated to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Every single pharmacologic response causes up-regulation and/or down-regulation of a number of biomarkers. Direct or indirect detection of them is the ultimate detection/prediction of a particular 
Urinary biomarkers
Up-regulation: IgA, small polypeptides, HSPG, apo-A1, α-hydroxybutyrate, oxalacetate, acetone, choline, formate, N-methylnicotinamide, serum albumin, alanine, sorbitol, uric acid, azelaic acid, β-alanine, isobutyrate, N-
3,4-dihydroxybutyric acid, glycolic acid, glycine, cis-aconitic acid, oxalic acid, β-hydroxybutyric acid, ribonic acid, mhydroxybenzoic acid, pregnanediol, valine, glucose; protein AMBP, malonate, m-hydroxyphenylacetate, hippuric acid, quinolinic acid, tyrosine, pseudouridine, 2,4-dihydroxypyrimidine, glutamate, fructose, 1,2,3-butanetriol, propylene glycol, phosphoric acid, sebacic acid, creatinine, hippurate, creatine, citrate, a-KG, TMAO (An and Gao, 2015).
Spinal cord injury
Up-regulation: p-Tau, NFs, NSE, GFAP, MBP, S-100β, cytokines, cysteine residues (CC, CXC and CX3X (CX3CL1)), MCP-1, chemokine (CXCL12 and its receptor CXCR4), TNF-R1, TNF-α, IL-1β, -2, -4, -5, -6, -7, -8, -10, -13, -15, -16, -17, IP-10, IFN-α, monokine induced by IFN-γ (MIG or CXCL9), MIP (Cruz et al., 2015) .
Alzheimer's disease
Up-regulation: Aβ-1-40, -42 in apo-E, p-tau/t-tau, DP-43, VILIP-1, YKL-40, HFABP (Mattsson et al., 2015; Blennow et al., 2015) ; Micro-RNAs (miR-486-5p, hsamiR-4299, let-7a-5p, let-7d-5p, let-7e-5p, let-7f-5p, let7g-5p, miR-1, miR-103, miR-122-5p, miR-125b, miR-126-3p, miR-1274a, miR-1294, miR-1306-5p, miR-133a, miR-137, miR138-5p, miR-139-5p, miR-142-3p, miR-143, miR-144-5p, miR-145, miR-146a, miR-148a-3p, miR-15a-5p, miR-17-3p, miR-17-5p, miR-181b, miR181c, miR-191-5p, miR-19a, miR-19b, miR-20a-5p, miR-210-3p, miR-21-5p, miR-219, miR-22p, miR-23a, miR-24-3p, miR-26b, miR-29a, miR-29b, miR-29b-3p, miR-29c, miR-301a-3p, miR-30e-5p, miR-31, miR-3200-3p, miR-335, miR-342-3p, miR-36, miR-365, miR-375, miR-449, miR-4674, miR-483-3p, miR-485-5p, miR-486-5p, miR-5001-3p, miR-502-3p, miR-545-3p, miR-548at-5p, miR-659-5p, miR-660-5p, miR-708, miR-885-5p, miR-9, miR-93, miR-98-5p); Down-regulation: Micro-RNAs (let-7b, let-7d-5p, miR-20a-5b, miR-221-3p, miR-100, miR-100-5p, miR-101-3p, miR-103, miR106a-5p, miR-106b-5p, miR-107, miR-125a-3p, miR125b, miR-126, miR-1274a, miR-137, miR-140-3p, miR-141-3p, miR-142-3p, miR-143-3p, miR-145-5p, miR-1468, miR-146a, miR-146b-5p, miR-148a, miR-148b-5p, miR-151a-3p, miR-151b, miR-155, miR-15a, miR-15a-5p, miR-15b, miR-15b-5p, miR-16-2-3p, miR-181b, miR-181c, miR-182-5p, miR-185-5p, miR-186, miR-186-5p, miR-18a, miR-18b-5p, miR-191, miR-191-5p, miR-193a-5p, miR-196b, miR-1975, miR-206, miR-20a-5p, miR-210-3p, miR-21-5p, miR-23b-3p, miR-24, miR26a-2-3p, miR-26b, miR-26b-3p, miR-27a-3p, miR-28-3p, miR-296, miR-29a/c, miR-301a-3p, miR-3065-5p, miR-30a, miR-30c-5p, miR-30d-5p, miR-30e-5p, miR-3158-3p, miR-320, miR-320a, miR-323b-5p, miR-331-5p, miR-335-5p, miR-338-3p, miR-342-3p, miR-342-5p, miR-34a, miR-3613-3p, miR-361-5p, miR-3622b-3p, miR-375, miR-378, miR-425, miR-425-5p, miR-4467, miR-451, miR-454, miR-4649-5p, miR-4781-3p, miR-483-3p, miR-483-5p, miR-5001-3p, miR-505, miR-545-3p, miR-550a-5p, miR-563, miR-582-5p, miR-596, miR-600, miR-6513-3p, miR-766, miR-885-5p, miR-9, miR-93, miR-93-5p, miR-98-5p) (Kumar and Reddy, 2016).
Schizophrenia
Up-regulation: BDNF, plasma pro-inflammatory cytokines, pro-inflammatory mediators (PGE2, COX-2, NFκB), 15d-PGJ2, IL-1, -4, -6, -10, -12, -17, TNF, CB1, -2, D2 (Penadés et al., 2015; Goff et al., 2016).
Rare neuromuscular diseases
Up-regulation: TNC, CK (Scotton et al., 2014).
Cognition and cognitive disorders
Up-regulation: Aβ amyloid, Aβ42/Tau (McConathy and Sheline, 2015); Micro-RNAs (miR-132/212, miR-134, miR-34a, miR-128b, miR-182, miR-183, miR-34, miR-124, miR-210, miR-278, miR-928, miR-932, miR-641, miR-7a, miR-26a, miR-124, miR-384-5p, miR-188, miR-191, miR-135a/b, miR-146b, miR-92, miR-125b, miR-34c, miR-181b, miR-1274a, miR-137, miR-195, miR-30e, miR-449a, miR-564, miR-548d, miR-572, miR-652, miR-34c-5p, miR-770-5p, Meso-miR-1, miR-16); Down-regulation: Micro-RNAs (miR-219, miR-132-3p, miR-34c, miR-137, miR-181c, miR-9, miR-29a/b, miR-34a, miR-146a, miR-125b, miR-432, miR-1271, miR-664, miR-18a, miR-22-3p, miR-106b, miR-107) (Woldemichael and Mansuy, 2016).
Amyotrophic lateral sclerosis (ALS)
Up-regulation: Proinflammatory monocyte, phenotype, microglia or cytokine expression, increased expression of CD4+ T cells, neurofilament in blood/CSF, T2 weighted MRI structural changes, alterations in RAN dipeptide proteins; Down-regulation: Tregs expression, complement activation, SOD1 in the CSF (Bakkar et al., 2015) .
Oxidative stress in neonatal brain injury
Up-regulation: F2-isoprostanes (IsoPs), isofurans (IsoFs), F4-neuroprostane, neurofurans, NO, isoforms of NOS (nNOS, eNOS), iNOS, superoxide, H 2 O 2 (Tataranno et al., 2015).
Psychiatric disorders
Up-regulation: OT and ADH (Grazia et al., 2016).
Cerebral ischemia
Up-regulation: NR2 peptide, NMDA-R antibody, glutamate, S100b, sRAGE, GFAP, vWF, VCAM-1, ICAM-1, VAP-1, MMP-9, MCP-1, fibronectins, CRP, ESR, TNF-α, IL-6, APC, Lp-PLA2, BNGF, BNP, Ddimer, ICH, SSAO, SVO, fibrinogen, PAI, TAFI, a2-antiplasmin, homocysteine, HDL, VLDL, apo-C-III, apoC-I, glycemia, copeptin, ferritin, NSE, p-Tau protein, albumin, GABA (Maestrini et al., 2016 ).
Depression
Up-regulation: DMNTB3, B-cell lymphoma 2), 5HT, 5HTT, 5-HT1A receptor, GRM4, polymorphisms in DGCR8 and AGO1, differences in lncRNA-mRNA expression, mtDNA, TEL) FKBP5, OGG1, IL-6, NF-κB, pro-inflammatory heterodimer (RelA:p50), apo-E2, CD8+, CD20+, CD4+ cells, STMN1 and P16INK4A, leukocytes, lymphocytes, platelets, PMBCs, BDNF; Micro-RNAs (pre-miR-30e, pre-miR-182, miR-429, miR-642, miR-589, miR-579, miR-941, miR-133a, miR-494, miR-107, miR-148a, miR-652, miR-425-3p , miR20b-3p, miR-433, miR-409-3p, miR-410, miR-485-3p, miR-133a, miR-145 , miR-130b, miR-505, miR-29b-2, miR-26b, miR-22, miR-26a, miR-664, miR-494, let-7d, let-7g, let-7e, let-7f, miR-629, miR-106b, miR-103, miR-191, miR-128, miR-502-3p, miR-374b, miR-132, miR30d, miR-500, miR-589, miR-183, miR-574-3p, miR-140-3p, miR-335, miR-361-5p , miR-132, miR-182 , miR-1972, miR26b, miR-4485, miR-4498, miR-4743, miR-511, miR-320a); Down-regulation: Micro-RNAs (miR-142-3p, miR-517b, miR-636, miR-1243, miR-381, miR-200c, miR-331-5p, miR-34c-5p, miR-770-5p, miR-135 , miR-1202, miR-144-5p, miR-451a, miR-17-5p, miR-223-3p) (Gururajan et al., 2016).
Epilepsy
Up-regulation: Glutamate receptors, nicotinic acetylcholine receptors, CDK5, CK2, TrKB, ADK, m-TOR, CRP, IL-1β, -6, COX-2, TGF-βR, CREB, MeCP2, REST, reelin, myoinositol, glutathione, N-acetyl aspartate, hemovanilic acid, hydroxyindolacetic acid; Micro-RNAs (miR-132, miR-34a, miR-146a) (Dixit et al., 2015) .
Brain injury
Up-regulation: S100β, enolase, GFAP, p-Tau (Kawata et al., 2016).
Glial tumors
Up-regulation: IDH (IDH1) mutations, promoter methylation of MGMT, chromosomal deletion of 1p/19q, TP53, mutations of EGFR and ATRX genes, and BRAF fusion via RAS/RAF/MEK/MAPK signaling pathway (Siegal, 2015) . 
Psychogenic nonepileptic seizures
Up-regulation: PRL, ACTH, CRH, CK, NSE, ghrelin and nesfatin-1, GABA, BDNF, WBC count, SERT (Sundararajan et al., 2016).
Neurodegenerative and vascular dementias
Up-regulation: Aβ40, Aβ42, Aβ42/40, Tau, p-Tau, PSEN mutations, Aβ42/p-Tau, α-sAPP, β-sAPP, YKL-40, YKL-40/Aβ42, IL-8, MCP-1, synaptic proteins neurogranin and SNAP-25, APOE-E4; Micro-RNAs (miR-29, miR-146a-5p, miR-27a-3p, miR-29a); Downregulation: Micro-RNAs (miR-27a-3p, miR-34a, miR125b, miR-146a, miR-146a) (Llorens et al., 2016 ). 
Systemic sclerosis

Cancers
Head and neck carcinoma
Up-regulation: Micro-RNAs (miR-425-5p, miR-93-5p) (Bedreag et al., 2015).
Esophageal cancer
Up-regulation: Micro-RNAs (miR-1246, miR-31, miR-1322) (Bedreag et al., 2015).
Nasopharyngeal cancer
Up-regulation: Micro-RNAs (miR-17, miR-20a, miR29c, miR-223) (Bedreag et al., 2015).
Biliary tract cancers
Up-regulation: ErbB-1/EGFR, ErbB-2/HER-2, ErbB-3/HER-3, VEGF, MAPK, P38MAPKs, ERKs, PIK/PTEN/AKT/mTOR, CA19-9, MMPs, CYFRA 21-1, SMAD4/DPC4, IDHs; Micro-RNAs (miR-135a, miR26a, miR-21, miR-192) (Hu and Yin, 2016).
Pancreatic cancer
Up-regulation: CA19-9 (Silva, 2015).
Thyroid cancer
Up-regulation: Thyroglobulin, calcitonin (Silva, 2015) .
Urothelial carcinoma
Mutations in UTX, MLL3, CREBBP-EP300, NCOR1, ARID1A, CHD6, STAG2, ESPL1, RAS oncogenes (KRAS, HRAS, NRAS), FGFR1/R3, ERBB2 (HER2), MET, NF1, TSC1;
Up-regulation: expression of orp53/Rb, RTK/RAS/PI3K/Akt/mTOR, histone-modifying genes (acetyl-transferases, methyl-transferases de-methylases) SWI/SNF nucleosome remodeling complex, such as ARID1A/1B, SMARCA2-A4/C1-C2, FGFR3, CD24/44, KRT5/6B/14/20, HER2, FOXA1, GATA3, TRIM24, XBP1, PPAR, BLCA-4, CYFRA 21-1, survivin, DD23, VEGF; CTLA-4, PD-1, CD279, PD-L1 (B7-H1); Micro-RNAs (miR-187, miR-18a, miR-25, miR-142-3p, miR-140-5p, miR-204) (Grivas et al., 2015).
Genitourinary malignancies
Up-regulation: Sipuleucel-T, the check point inhibitors,
anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-PD-L1, anti-PD-1, prostate stem cell antigen, MUC1/2, Globo-H, GM2, EGFR, orerbB2, gene markers included KLK2/3, HOXB13, GRHL2, and FOXA1, CD33+, CD11b+, CD15+, CD14+, CD8+ cells, TILs, IL-2, -4, -5, -10, -17, -26, 22RA1, -1RAPL1, -1F5, -17RB, -17RE, -20, -21, -28A, TRAF2; TGF-β , CTLA-4, lymph node, PD-L1/L2, mutation in PDCD1 gene, ALC, CA9, IgG1, fractalkine (CX3CL1), Th1, STAT3 signaling, lymphocyte populations (CD3/CD45RO, CD3/CD8 or CD8/CD45RO), HER-2/neu (p185erbB-2), EGFR, Bcl-2, p53, BRAF mutation, TNM-I (Slovin et al., 2016).
Colon cancer
Carcinoembryonic antigen (Silva, 2015) ; KRAS (Buchbinder and Flaherty, 2016). 
Colorectal cancer
Mutations in KRAS, RAS NRAS, EGFR
Bladder cancer
Up-regulation: NMP22, FGFR3, BTA, ImmunoCyt/uCyt1, SOX1, a specific LINE-1 element, IL-1, IRAK3, OTX1, ONECUT2, OSR1, HDAC-1/2 overexpression, KLF4, survivin (BIRC5 or EPR-1), AURKA, NLR, pRB, p21, -27, HRAS, PI3K, CD44v6, VEGFR1/2, HYAL-1, CA-IX, PFKFB4; Micro-RNAs (miR-96, miR-138, miR-126, miR-182, miR-143, miR-222, miR-21, miR-133b, miR-518c-5p, miR-452, miR-129, miR-99a, miR-100, miR-141, miR-639); Downregulation: Micro-RNAs (miR-200c, miR-99a, miR-100, miR-29c) (Bedreag et al., 2015; Lucca et al., 2015) .
Testicular cancer
Up-regulation: Human chorionic gonadotropin-β (Silva, 2015).
Cervical cancer
Up-regulation: HPV DNA, SCC-Ag, CYFRA, CEA, COX-2, sCD44, matrix, MMPs (MMP-2, -9, TIMPs (Dasari et al., 2015).
Prostate cancer
Micro-RNAs (Up-regulation: miR-16, miR-92a, miR-103, miR-107, miR-197, miR-34b, miR-328, miR-485-3p, miR-92b, miR-636, miR-640, miR-766, miR-885-5p) (Bedreag et al., 2015) ; PSA (Buchbinder and Flaherty, 2016).
Overian cancer
CA125; Micro-RNAs (Up-regulation: miR-21, miR-92, miR-93, miR-126, miR-92a) (Bedreag et al., 2015) .
Breast cancer
Up-regulation: Micro-RNAs (miR-10b, miR-341, miR-195) (Bedreag et al., 2015) ; ER, PR, CA15-3, HER2 (Silva, 2015) ; EGFR, TNBC, HER1/ErbB1, HER2/new/ErbB2, HER3/ ErbB3, and HER4/ErbB4, TNCs, Bcl-2, adhesion molecule (CD44/CD24), BRCA1/A2, p53, p63, p53siRNA gene, p16INK4a, cytokeratins 5, 14, and 17 (Kallel et al., 2015) .
T-cell lymphoma
Mutations in GATA3, TBX21, STAT3 genes, Upregulation: IL-4,-5, -6, -10, -13, -18, -21, Bcl-6, CXCL13, PD-1, VEGF, JAK1/2 expression (Tse and Kwong, 2015).
Melanoma
Lymphocyte count, lymphocytic infiltrates; Upregulation: LDH; mutations in viral oncogene homolog B1 (BRAF; especially V600 E/K and non-V600 E/K), RAS, NF1, KIT, GNA11/GNAQ, TP53/CDKN2A, IDH1, BAP1; melanoma biomarkers-MIA, S-100B, and TYRP2; IL-2, CTLA-4, PD-1 and PD-L1 antibodies, VGEF expression, ICOS, NY-ESO-1, IFN-γ, pre-existing CD8+ T cells, LCK protein expression; Downregulation: CTNNB1 (b-catenin) score (Buchbinder and Flaherty, 2016 ). 
Complications
Renal cancer
Up-regulation: Micro-RNA (miR-1233) (Bedreag et al., 2015).
Kidney injury
Up-regulation: L-FABP, NGAL, αGST, πGST, TLR4, NF-κB, cytokines, FENα, albumin, kidney injury molecule-1 (Belcher, 2015) ; FGF-23 (Wasung et al., 2015) ; TIMP-2, IGFBP7, IL-18, CI-AKI, KIM-1 and Cystatin-C (McMahon and Koyner, 2016). FHIT, p19ras, CHRNA3 SNP, telomere related genes, miRs, Bcl-2, K-ras, methylation of p16INK4a, cdc25B, KLF6, caspase 7, survivin, p16, KLK5, -7, RRM1, RASSF1A, RUNX3, SEPP1, -15, hGPX1, cDNA and cRNA (Altintas and Tothill, 2013 ).
Renal cell carcinoma
Up-regulation: VEGF (VEGF-
A
Interstitial lung diseases
Up-regulation: MMP7, SP-A, -D, KL-6, CCL-18, YKL-40, MUC5B (Nathan et al., 2015). 
Lung cancer
Mutations in
Childhood asthma
Up
Community-acquired pneumonia
Hepatocellular carcinoma
Up-regulation: Micro-RNAs (miR-9-3p, miR-9, miR10a, miR-10b, miR-15a, miR-18a, miR-21, miR-27a, miR-92, miR-96) (Bedreag et al., 2015) .
Hepatotoxicity
Up-regulation: GDH, GSH, P-JNK, cytokeratin-18, miR-122, HMBG-1, nDNA, ASS fragments, AST, ALT, BHMT, DPYS, FAH, FBP1, SAMe, COMT, CPS1, mtDNA, nDNA, keratins 8, 18, caspase-3, -7, -9, CES-1, HMGB-1, IL-6, -8 (Siemionow et al., 2016).
Non-alcoholic fatty liver disease
Altered genes encoding chromatin-remodeling enzymes, including jumonji C-domain-containing histone demethylases; Up-regulation: Micro-RNAs (miR-122, miR-21, miR-34a, miR-451, miR-29, miR-200b, miR-155, miR-200a, miR-200b and miR-429), TLR-4 (i.e.-Asp299Gly and Thr399IleTLR4); Genes: CYP2A12, CYP2C38, CYP4A10, CYP4A14, IL-1R-related molecule, aldo-keto reductase family 1 member B10, keratin, type I cytoskeletal 23, FGF-21, GST-A2, AR, NR subfamily 2 group F member 1, HNF-α4, retinoic acid receptorrelated orphan receptor 1 α, lymphocyte antigen 6D, fatspecific protein 27, aquaporin 4, UK1, tearoyl-CoA desaturase-1, CD36, CKα, P4P3K, catalytic subunit type 2 γ, insulin induced gene 2, PP1, regulatory subunit 3C, PGD2 synthase 21 kDa, decorin, EMP1, IjB kinase b interacting protein, PPARγ; Protein: FABP, 17β-HSD13, apo-A1, E, protein disulfide isomerase, CYFRA-8, -18, vimentin, MUP2, methylenetetrahydrofolate dehydrogenase 1, LDH-A, annexin A5, DCRT2, cadherin 2, guanosinetriphosphate-binding protein SAR1b; Metabonomic:
1,3-dihydroxyacetone, 12-hydroxyeicosatetraenoic acid, adenosine, butyrylcarnitine, carnitine, cholesterol esters, choline, di-homo-c-linolenic acid, free cholesterol, fructose, glucose, glutamate, glutamyl dipeptides, glutamyl leucin, glutamyl phenylalanine, glutamyl tyrosine, glutamyl valine, glycero pc, glycerylphosphorylethanolamine, glycine conjugates, histidine, inosine, isoleucine, lactate, leucine, linoleic acid, lipids, lysine, methionine sulfoxide, methionine, non-esterified fatty acid, oleic acid, oxidized glutathione, phenylalanine, sarcosine, sorbitol, taurine, taurochendeoxycholate, taurocholate, taurocholic acid, taurodeoxycholic acid, tauro-β-muricholate, tg, tyrosin, tyrosine, uridine, valine, α-hydroxybutyrate; Down-regulation: Genes: glucose-6-phosphatase, PP2, regulatory subunit B, δ, flavin containing monooxygenase 3, CYP7B1, TF3I, synaptotagmin 1, 3-ketosteroid reductase; Proteins: HSP70, senescence marker, p30, chaperonin GroEL, Sadenosylhomocysteine hydrolase, GPx1, GT1, methylthioadenosine, phosphorylase, methionine, AT1α, EGFR, six-transmembrane epithelial antigen of prostate 4, translocation protein SEC62; Metabonomic: 10-undecenoate, 3- 
Liver cirrhosis
Up-regulation: Cystatin C, BUN, Beta-2 microglobulin (β2M), GFR, UO, SCr, NGAL, IL-18, 
Human tears
Up-regulation: MMP-9, IgE and lactoferrin (Azkargorta et al., 2016).
Problems in germ cell production
Up-regulation: LDH, α-Fetoprotein (Silva, 2015).
Posttraumatic stress disorder
Up-regulation: Corticotropin-releasing hormone, arginine vasopressin, CRP, HR, IL-1β, -2, -6, norepinephrine, glucocorticoid negative feedback, pituitary adenylate cyclase-activating polypeptide, dehydroepiandrosterone, dehydroepiandrosterone sulfate, ghrelin, insulin, serotonin 1A receptor, NF-κB, TNF-α, immune cell sensitivity to glucocorticoids, amygdale reactivity; Down-regulation: Allopregnanolone, estradiol, HR variability, serotonin transporter; NF-κB, neuropeptide Y, testosterone, cortisol, endocannabinoids, hippocampus activity (Michopoulos et al., 2015) .
Sickle cell disease
Up-regulation: HbS, HbF, HbSF, MCV, HbA2, ISCs, CD36 (glycoprotein IV), integrin a4b1 (very late activation antigen-4) to VCAM-1 and fibronectin, integrin α4β1, leukocyte adhesion molecules (L-selectin and αMβ2), CRP, ESR, sPLA2, IL-2, -3, -6, -8, -10, urinary cysteinyl LTE4, PGE2, CA 15-3, sCD40 ligand, HSP-70, ferritin, angiopoietin 1/2, stromal derived factor 1, TNF-α, TNFR-1, LDH-1, haptoglobin, Hb, reticulocyte count, RBC survival, blood coagulation, GSH/GSSG, stroke, BP, renal disease, TG, LDH, FMD, VEGF, PGF, ET-1, vitamin D, ALP, TRV, NT-proBNP, cTnI, PIT, HJBs, pitted RBCs (Damanhouri et al., 2015) .
Metabolic syndrome
Up-regulation: BP, LDL-C, insulin, glucose, TG; Micro-RNAs (miR-17, miR-197, miR-509-5p, miR-92a, miR-320a) (O"Neill et al., 2016).
Acute graft-versus-host disease
Up-regulation: ST2, TNFR1, IL-7, sBAFF, REG3a, S100, TIM-3, CK-18, HGF, elafin; Micro-RNAs (miR-155, miR-586, miR-423, miR-199a-3p, miR-93, miR-377) (Ali et al., 2016 ).
Non-communicable diseases
Up-regulation: IL-1R1, -8, -4, -5, -10, -12, -13, -17A, -17F, -17AF, -18, -31, -9, -17E, -25, -21, -22, -23R, -26, LPS, CD4+ CD25+ T cells, TNF-α, TLR4, sICAM-1, LL-37, CCL17, 22, 27, 28; Micro-RNA (miR-203, miR-483-5p, miR-146a, miR-21, miR-638, miR-125-5p, miR-342-3p, miR-365-3p), carnitine, lactic acid, CD5L, apo-E, IgA, -G, -E, calprotectin, sFasL, polyubiquitin C, filaggrin, calmodulin-like protein 5, FoxP3, FENO/eosinophils/periostin, VOCs, ANCA, ASCA, antiOmpC, anti-glycoprotein 2, adiponectin, EPCs, EMPs, CRP, insulin, bradykinin, naringenin, L-thyronine, citrate, succinate, creatinine, glutaric acid, 3-aminoisobutyric acid, p-Hydroxyphenyllactate (Skevaki et al., 2016 ).
Conclusion
Information of this article may be helpful for the researchers those are working in medical sciences, especially pharmaceutical sciences -in drug discovery and development.
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